ClearPoint Neuro, Inc.CLPTNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR-11.3%
5Y CAGR-28.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-11.3%/yr
Annual compound
5Y CAGR
-28.9%/yr
Recent acceleration
Percentile
P50
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 12.14% |
| 2024 | 5.83% |
| 2023 | 7.48% |
| 2022 | 17.38% |
| 2021 | 98.06% |
| 2020 | 66.76% |
| 2019 | 21.64% |
| 2018 | -17.90% |
| 2017 | 7.06% |
| 2016 | 34.27% |